spironolactone 25 mg orally once daily

DRUG2 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Massachusetts General Hospital

Conditions

DiabetesGestational HypertensionHypertensionKidney DiseasePreeclampsia

Phase 2

Improving Outcomes in Patients With Kidney Disease Due to Diabetes

CompletedNCT00381134

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Diabetes, Hypertension, Kidney Disease

Start: 2003-07-31End: 2006-12-31Target: 92Updated: 2010-03-02

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

RecruitingNCT07041281

Massachusetts General HospitalGestational Hypertension, Preeclampsia

Start: 2025-10-16End: 2029-03-02Target: 204Updated: 2026-04-03

Related Papers

Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes.

2020-05-116 citations

Effect of Losartan and Spironolactone on Triglyceride-Rich Lipoproteins in Diabetic Nephropathy

Journal of Investigative Medicine2016-07-0813 citations